Adaptimmune Therapeutics plc

News & Events

Press Releases

In The Media

1. Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

   Newsfile MAY 7, 2025 12:00 PM EDT
   Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmu...
   READ ARTICLE

2. Adaptimmune Provides Q4 and Full Year 2024 Business Update

   Newsfile MAR 20, 2025 7:00 AM EDT
   TECELRA ® launch momentum accelerating – 10 patients apheresed in Q1 2025 and ...
   READ ARTICLE

3. Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

   Newsfile MAR 12, 2025 4:54 PM EDT
   Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adapti...
   READ ARTICLE

4. Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

   Newsfile JAN 30, 2025 4:00 PM EST
   Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adap...
   READ ARTICLE

5. Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

   Newsfile JAN 13, 2025 8:00 AM EST
   The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business upda...
   READ ARTICLE

6. Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

   Newsfile DEC 19, 2024 7:30 AM EST
   Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Offic...
   READ ARTICLE

7. First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

   Newsfile DEC 2, 2024 4:00 PM EST
   Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor...
   READ ARTICLE

8. Adaptimmune Reports Q3 2024 Financial and Business Updates

   Newsfile NOV 13, 2024 4:05 PM EST
   Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient t...
   READ ARTICLE

9. Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

   Newsfile NOV 13, 2024 9:00 AM EST
   42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with l...
   READ ARTICLE

10. Adaptimmune to Participate in Scientific and Medical Conferences this November and December

    Newsfile NOV 5, 2024 9:19 AM EST
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adap...
    READ ARTICLE